Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpress: Imetelstat in HR MDS or AML Failing HMA-based Therapy
NCT05583552Phase 2Completed
- Sponsor
- GCP-Service International
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of imetelstat in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by GCP-Service International. Started Jun 2023; status: completed.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05583552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583552.